Compass Therapeutics Inc. (CMPX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $139.35M
Last updated: Nov 17, 2026 at 11:04 AM ET
Compass Therapeutics Inc. (CMPX) Competitors
The companies most similar to Compass Therapeutics are Invivyd (IVVD), Protara Therapeutics (TARA) and Pyxis Oncology (PYXS). By market cap, Compass Therapeutics ranks 9th of the 13 companies on this page; Prelude Therapeutics (PRLD) is the largest at $275.32M.
Peer Comparison
CMPX's revenue growth of 0.0% is in line with the peer median. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Compass Therapeutics (CMPX) | $139.35M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Invivyd Inc. (IVVD) | $171.58M | N/A | 2.9x | -183.9% | N/A | 21.2% | 0.00% |
| Protara Therapeutics Inc (TARA) | $155.77M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Pyxis Oncology Inc (PYXS) | $188.98M | N/A | 11.6x | 0.0% | N/A | 0.0% | 0.00% |
| OUTLOOK THERAPEUTICS INC (OTLK) | $100.54M | N/A | N/A | 0.0% | -776.9% | -99.4% | 0.00% |
| Fate Therapeutics Inc (FATE) | $155.74M | N/A | 29.7x | 0.0% | -51.3% | 9.2% | 0.00% |
| Cellectis SA (CLLS) | $118.86M | N/A | 1.8x | 0.0% | -74.1% | -85.4% | 0.00% |
| Voyager Therapeutics Inc (VYGR) | $107.66M | N/A | 4.0x | 0.0% | N/A | -70.0% | 0.00% |
| Upstream Bio, Inc. (UPB) | $152.38M | N/A | 41.0x | 0.0% | N/A | -42.2% | 0.00% |
| Innate Pharma (IPHA) | $154.15M | N/A | 17.6x | 0.0% | 489.8% | 16.5% | 0.00% |
| Keros Therapeutics Inc (KROS) | $202.13M | N/A | 4.9x | -151.4% | N/A | 180.5% | 0.00% |
| Prelude Therapeutics Inc (PRLD) | $275.32M | N/A | 16.3x | -269.7% | N/A | 41.0% | 0.00% |
| PDS Biotechnology Corp (PDSB) | $107.07M | N/A | N/A | 0.0% | -149.8% | 0.0% | 0.00% |
| Peer median | $154.94M | N/A | 11.6x | 0.0% | -74.1% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Compass Therapeutics, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Invivyd Inc. (IVVD) | Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on the discovery... | IVVD competitors |
| Protara Therapeutics Inc (TARA) | Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to identifying and promoting transformative therapies for the treatment... | TARA competitors |
| Pyxis Oncology Inc (PYXS) | Pyxis Oncology, Inc., a preclinical biotechnology company, is dedicated to developing antibody-drug conjugate (ADC) and monoclonal antibody (mAb)... | PYXS competitors |
| OUTLOOK THERAPEUTICS INC (OTLK) | Outlook Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic... | OTLK competitors |
| Fate Therapeutics Inc (FATE) | Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders globally. | FATE competitors |
| Cellectis SA (CLLS) | Cellectis SA, a clinical-stage biotechnology company, develops immuno-oncology products based on gene-edited T cells that express chimeric antigen receptors... | CLLS competitors |
| Voyager Therapeutics Inc (VYGR) | Voyager Therapeutics, Inc., a clinical-stage gene therapy company, is focused on developing treatments for patients with severe neurological diseases. | VYGR competitors |
| Upstream Bio, Inc. (UPB) | Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. | UPB competitors |
| Innate Pharma (IPHA) | Innate Pharma SA, a biotechnology company, discovers, develops and markets therapeutic antibodies for the treatment of oncological indications in France... | |
| Keros Therapeutics Inc (KROS) | Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery... | KROS competitors |
| Prelude Therapeutics Inc (PRLD) | Prelude Therapeutics Incorporated, a precision clinical-stage oncology company, focuses on the discovery and development of small molecule therapies optimized... | PRLD competitors |
| PDS Biotechnology Corp (PDSB) | PDS Biotechnology Corporation, a clinical-phase biopharmaceutical company, is focused on developing multifunctional cancer immunotherapies. | PDSB competitors |
Frequently Asked Questions About CMPX
Who are Compass Therapeutics' main competitors?
The companies most similar to Compass Therapeutics include Invivyd (IVVD), Protara Therapeutics (TARA), Pyxis Oncology (PYXS), OUTLOOK THERAPEUTICS INC (OTLK) and Fate Therapeutics (FATE), listed from the closest match.
Who is Compass Therapeutics' biggest competitor?
Prelude Therapeutics (PRLD) is the largest of the similar companies at $275.32M; Invivyd (IVVD) is the closest match by business profile, size, sector and industry.
How does CMPX stock compare with its competitors?
CMPX's net margin is 0.0% against a peer median of 0.0%.
Which of Compass Therapeutics' competitors pays a higher dividend?
Compass Therapeutics pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Compass Therapeutics bigger than its competitors?
No. Compass Therapeutics is 9th by market cap among the 13 companies on this page; the largest is Prelude Therapeutics (PRLD) at $275.32M.
CMPX pages: Overview, Earnings, Forecast, Financials, Competitors